Biocartis Group NV (LTS:0R72) Total Equity: €-53.99 Mil (As of Jun. 2023)


LTS:0R72 Biocartis Group NV LTS:0R72
14 GF Score
Price €0.30
View Full Analysis

What is Biocartis Group NV Total Equity?

Biocartis Group NV LTS:0R72 14 Total Equity is €-53.99 Mil as of Jun. 2023. GuruFocus rates LTS:0R72 with a GF Score™ of 14/100.

Biocartis Group NV's total equity for the quarter that ended in Jun. 2023 was €-53.99 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Biocartis Group NV Total Equity Historical Data

* Premium members only.

The historical data trend for Biocartis Group NV's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocartis Group NV Total Equity Chart

Biocartis Group NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 87.35 84.48 36.82 -33.90 -30.28

Biocartis Group NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.23 -33.90 -61.77 -30.28 -53.99
LTS:0R72
14GF Score
Biocartis Group NV LTS:0R72
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocartis Group NV Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Biocartis Group NV's Total Equity for the fiscal year that ended in Dec. 2022 is calculated as

Total Equity=Total Assets(Q: Dec. 2022 )-Total Liabilities(Q: Dec. 2022 )
=114.277-144.561
=-30.28

Biocartis Group NV's Total Equity for the quarter that ended in Jun. 2023 is calculated as

Total Equity=Total Assets(Q: Jun. 2023 )-Total Liabilities(Q: Jun. 2023 )
=112.981-166.968
=-53.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €-53.99 Mil mean?
Biocartis Group NV (LTS:0R72) has a Total Equity of €-53.99 Mil as of Jun. 2023. The total amount of equity as record on a company's balance sheet. View historical data for Biocartis Group NV and its competitors.
Is Biocartis Group NV's Total Equity too high?
Biocartis Group NV's current Total Equity is €-53.99 Mil. Overall, Biocartis Group NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Biocartis Group NV's Total Equity compare to TMO and DHR?
Biocartis Group NV's Total Equity of €-53.99 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Diagnostics & Research company?
A good Total Equity depends on the Medical Diagnostics & Research industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Biocartis Group NV and its competitors. Biocartis Group NV's current Total Equity is €-53.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocartis Group NV stock overvalued right now?
Biocartis Group NV (LTS:0R72) has a current Total Equity of €-53.99 Mil. The current Total Equity is €-53.99 Mil. Biocartis Group NV's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Biocartis Group NV (LTS:0R72), the current Total Equity is €-53.99 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biocartis Group NV Business Description

Address Generaal de Wittelaan 11 B, Mechelen, BEL, 2800
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an Meet Idylla molecular diagnostic system for oncology and infectious disease segments.
14GF Score

Get the complete analysis for LTS:0R72

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price